ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial.
Patrice Carde(Institut Gustave Roussy), Nicolas Mounier(Centre Hospitalier Universitaire de Nice), Serge Bologna(Centre Hospitalier Régional et Universitaire de Nancy), Guy Cantin(Hôpital de l'Enfant-Jésus), Christophe Fermé(Institut Gustave Roussy), Isabelle Gaillard(Erasmus Hospital), Catherine Fortpied(European Organisation for Research and Treatment of Cancer), Franck Morschhauser(Hôpital Claude Huriez), Hussein Khaled(Centre Hospitalier Universitaire de Lille), Bengt Glimelius(Uppsala University), Pieternella J. Lugtenburg(Erasmus MC Cancer Institute), Denis Caillot, Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Igor Aurer(University Hospital Centre Zagreb), Pauline Brice(Hôpital Saint-Louis), Max Wolf(Peter MacCallum Cancer Centre), Matthew D. Seftel(CancerCare Manitoba), Matthias Karrasch(Unknown), Bertrand Coiffier(Unknown)
Cited by 50
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k